The Princess Margaret Living Biobank (PMLB) offers Patient Derived tumor Organoid (PDO) and Xenograft (PDX) models and associated turnkey services for research studies.
Scientific Director
Dr. Ming-Sound Tsao
Scientific Advisory Committee
Drs. Laurie Ailles, Robert Bristow, David Cescon, David Hedley, Geoffrey Liu, Catherine O’Brien, Trevor Pugh and Robert Rottapel
Scientific Managers
Dr. Niki Radulovich (Core Organoid)
Dr. Nhu-An Pham (Core PDX)
Supporting UHN Facilities
- Animal Resources Centre (Badru Moloo, Christine Quarrington, Janet Sunohara-Neilson)
- Biospecimen Sciences Program (Hal Berman, Dianne Chadwick, Afia Hasnain)
- PM Genomics Centre (Neil Winegarden)
- Bioinformatics Core (Carl Virtanen)
- DDP-AMPL Biomarker Lab (Michael Cabanero, Nhu-An Pham, Ming Tsao)
- AOMF (James Jonkman)
- Technology Development & Commercialization (Bharti Ranavaya)
Organoid Personnel
Jennifer Haynes (Colon)
Gaetano Zafarana (Prostate)
Laura Tamblyn (Pancreas)
Christine Ng and Kelly Shi (Lung)
Herman Chui and Zvi Shalev (Ovary)
Kelsie Thu and Samah El (Breast)
PDX Technologists
Mary Cao, Yuhui Wang and Jalna Meens
- Available PDO models by primary tumor site
- Colon
- Lung
- Pancreas
- Others... methods in development
A PDO is a three-dimensional structure grown from cancer cells in a gel-like compound using media containing components which support renewal. PDOs are amenable to faster expansion times in culture under the appropriate conditions and result in higher throughput compared to PDX models.
- Available PDX models by primary tumor site
- Breast
- Cervix
- Colon
- Esophageal
- Head & Neck
- Lung
- Mesothelium
- Ovarian
- Pancreas
A PDX is created when tissue/cells from a patient’s tumor is implanted directly into an immunodeficient mouse host. Once established as a xenograft model, the tumor specimen is extracted, divided and further expanded in multiple mice for cryobanking and experimentation.
-
Scientific Manager, Core PDX416-634-8721TMDT 14-301
-
Scientific Manager, Core Organoid416-634-8721TMDT 14-301